In September of 2018, Principal Investigator Grace Dy shared the initial results the first Roswell Park trial. They found that the combination of CIMAvax with the PD-1 inhibitor checkpoint inhibitor nivolumab was safe and well-tolerated in 13 people with advanced non-small cell lung cancer (NSCLC) when administered at the doses normally recommended for each agent individually. Notably, they observed durable responses to the combination treatment in patients who were unlikely to benefit from nivolumab alone due to low tumor levels of PD-L1, suggesting that the combination may work better than either agent individually.
The final results of this early trial were released in March 2019. The results were in line with the September 2018 report, with the additional finding that that more patients receiving combination therapy in this trial were more likely to develop robust early antibody responses to CIMAvax as compared with what had been observed in earlier studies with CIMAvax alone.